Upgrade to SI Premium - Free Trial

INmune Bio (INMB)

1.61 +0.01 (0.63%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/4/26)

Latest Headlines

Form 8-K Inmune Bio, Inc. For: Oct 21 October 21, 2026 9:01 AM - SEC Filing INmune Bio submits pre-MAA package for Ebstrocel, targets mid-2027 UK approval October 21, 2026 7:16 AM - StreetInsider INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027 October 21, 2026 7:15 AM - StreetInsider INmune Bio signs distribution deal with Uniphar for Ebstrocel access October 21, 2026 7:00 AM - StreetInsider INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar October 21, 2026 7:00 AM - StreetInsider INmune Bio and Quantum Computing Inc. partner on Alzheimer's drug research October 14, 2026 8:45 AM - StreetInsider INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™ October 14, 2026 8:45 AM - StreetInsider INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™ October 14, 2026 8:30 AM - PR NewsWire INmune Bio to Attend the 2026 Maxim Growth Summit October 6, 2026 9:00 AM - StreetInsider Form 4 Inmune Bio, Inc. For: Sep 15 Filed by: Clark Ronnie Duane September 23, 2026 6:06 AM - SEC Filing Form 3 Inmune Bio, Inc. For: Sep 08 Filed by: Clark Ronnie Duane September 23, 2026 6:04 AM - SEC Filing Form 8-K Inmune Bio, Inc. For: Sep 08 September 22, 2026 5:10 PM - SEC Filing Form 4 Inmune Bio, Inc. For: Sep 15 Filed by: SAPIRSTEIN JAMES September 17, 2026 1:44 PM - SEC Filing Form 3 Inmune Bio, Inc. For: Sep 08 Filed by: SAPIRSTEIN JAMES September 16, 2026 8:05 PM - SEC Filing Form 8-K Inmune Bio, Inc. For: Sep 08 September 14, 2026 4:06 PM - SEC Filing INmune Bio adds two executives to its board of directors September 14, 2026 7:00 AM - StreetInsider INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board September 14, 2026 7:00 AM - StreetInsider INmune Bio to Present at the H.C. Wainwright Global Investment Conference September 9, 2026 8:00 AM - StreetInsider INmune Bio files for EMA orphan drug status for its RDEB cell therapy August 26, 2026 7:02 AM - StreetInsider INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings August 26, 2026 7:00 AM - StreetInsider INmune Bio, Inc. (INMB) Tops Q2 EPS by 14c August 6, 2026 5:38 PM - StreetInsider Form 10-Q Inmune Bio, Inc. For: Jun 30 August 6, 2026 4:10 PM - SEC Filing INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress August 6, 2026 4:00 PM - StreetInsider Form 8-K Inmune Bio, Inc. For: Jul 31 July 31, 2026 4:06 PM - SEC Filing INmune Bio receives $4.6M in R&D rebates from UK and Australia July 31, 2026 7:00 AM - StreetInsider INmune Bio Receives R&D Rebates of Approximately $4.6 Million July 31, 2026 7:00 AM - Globe NewsWire INmune Bio Receives R&D Rebates of Approximately $4.6 Million July 31, 2026 7:00 AM - StreetInsider INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th July 31, 2026 7:00 AM - StreetInsider INmune Bio forms advisory board for CORDStrom cell therapy platform July 30, 2026 7:00 AM - StreetInsider INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform July 30, 2026 7:00 AM - StreetInsider Full Article List